Ginell R. Post

University of Arkansas for Medical Sciences — United States

Medicine · Health Sciences

21h-index1.7kcitations129works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(59), Chronic Lymphocytic Leukemia Research(45), Receptor Mechanisms and Signaling(11), Acute Lymphoblastic Leukemia research(10), Protein Kinase Regulation and GTPase Signaling(9)

Publications129 total

Cell type- and species-specific regulation of hepatic lncRNAs by TCDD-activated aryl hydrocarbon receptor
Scientific Reports·2025· 1 citedOpen Access
Acute Myeloid Leukemia with Hemophagocytosis: Diagnostic Cues and Potential Pitfalls.
PubMed·2025
Strategies to Optimize Overutilization of Provider-Ordered Peripheral Blood Smear Review in an University Hospital Setting
Blood·2024
Unexpected Presentations of Histiocytic Disorders as Mass Lesions in the Central Nervous System and Spine
American Journal of Clinical Pathology·2024Open Access
Figure S10 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024Open Access
Figure S4 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024Open Access
Table S10 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024Open Access
Figure S3 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024Open Access
Table S7 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024Open Access
Table S6 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024Open Access
Table S2 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024Open Access
Figure S8 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024Open Access
Figure S4 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024Open Access
Figure S11 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024Open Access
Figure S8 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024Open Access
Figure S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024Open Access
Table S11 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024Open Access
Table S6 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024Open Access
Table S5 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024Open Access
Figure S7 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
2024Open Access
page 1 of 7Next →

Frequent Co-authors

Steven R. Post(8), Joan Heller Brown(6), John Lazarchick(5), David Goldstein(4), Bruce A. Waldrop(4), Michael T. Piascik(4), Daisy Alapat(4), Mark S. Smeltzer(3), Glyn Dawson(3), Lila R. Collins(3), Dan F. McCune(3), Stephanie E. Edelmann(3), Dianne M. Perez(3), Frits van Rhee(3), Christopher C. Glembotski(2), A. Zielińska(2), Karen E. Beenken(2), Lara N. Mrak(2), Horace J. Spencer(2), Robert A. Skinner(2)